Research Collaboration and Sub-licensing Agreements (Details) € in Thousands					3 Months Ended		9 Months Ended
	Jun. 24, 2020	May 07, 2019 antibody_and_vaccine protein	Jun. 30, 2017 USD ($)	Jun. 30, 2017 EUR (€)	Sep. 30, 2020 USD ($)	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($)	Sep. 30, 2019 USD ($)	Jul. 08, 2020 shares	Apr. 26, 2019	Jun. 30, 2017 EUR (€)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Duration of agreement			2 years	2 years
Payment for research and development agreement			$ 1,100,000	€ 1,000
Research and development - related party | $					$ 0	$ 101,849	$ 0	$ 827,632
Revenue from collaborative arrangement, recognized | $					$ 70,000		$ 244,000
Collaborative Arrangement | Serum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of antibodies and vaccines for development and commercialization | antibody_and_vaccine		12
Option to obtain exclusive commercial sub-license for number of proteins | protein		12
Research funding, milestone payments and royalties, period		15 years
Novovet
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Equity percentage										20.00%
Alphazyme
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Percentage of ownership after transaction	2.50%
ID Biologics, In
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of shares to be received (in shares) | shares									129,611
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners									0.37%
ID Biologics, In | Signing of the Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Vesting percentages									50.00%
ID Biologics, In | Upon the completion of Sept 3
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Vesting percentages									25.00%
ID Biologics, In | End of project
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Vesting percentages									25.00%
RSA
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payment for research and development agreement | €				€ 1,000
Payment for additional development and commercialization | €											€ 1,500
RSA | Minimum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue sharing, percentage			50.00%	50.00%
RSA | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue sharing, percentage			75.00%	75.00%
RSA | BDI Holdings
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Equity interest acquired			16.10%	16.10%
RSA | VLPbio
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Equity interest acquired			3.30%	3.30%
RSA | BDI
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Duration of agreement			2 years	2 years
Obligation for payment for research and development, minimum | €											936
Obligation for payment for research and development, maximum | €											€ 8,000
RSA | BDI | Minimum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue sharing, percentage			50.00%	50.00%
RSA | BDI | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue sharing, percentage			75.00%	75.00%
SFA
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Duration of agreement			2 years	2 years
Obligation for payment for research and development, minimum | $			$ 1,000,000
Outstanding commitment | $			$ 1,000,000